title: Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
abstract: BACKGROUND
  Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis. Treatment strategies for SBA have not been clearly established.
  
  
  METHODS
  All patients with SBA treated using a combination of cisplatin and irinotecan (IP) as first-line chemotherapy at the National Cancer Center Hospital in Japan between January 1999 and February 2007 were studied retrospectively.
  
  
  RESULTS
  Eight patients received IP as first-line chemotherapy. The median follow-up was 9.5 months (range, 4.2-37.5 months). The median number of cycles of IP was three (range, 1-5). The overall response rate (complete or partial response) was 12.5% (complete response, n = 0; partial response, n = 1). The disease control rate (complete or partial response or stable disease) was 75%. The median time to treatment failure was 4.5 months (95% confidence interval, 0.9-5.8 months), and overall survival was 17.3 months (range, 1.9-21.3 months). The most common adverse events were neutropenia and anorexia.
  
  
  CONCLUSIONS
  IP combination chemotherapy may be an acceptable option for patients with SBA. Further studies are warranted to determine the optimal chemotherapeutic regimen for SBA.
authors.affiliation: Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Ono
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Shirao
authors.forename: Atsuo
authors.initials: A
authors.lastname: Takashima
authors.forename: Chigusa
authors.initials: C
authors.lastname: Morizane
authors.forename: Natsuko
authors.initials: N
authors.lastname: Okita
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Hirashima
authors.forename: Takako
authors.initials: T
authors.lastname: Eguchi-Nakajima
authors.forename: Ken
authors.initials: K
authors.lastname: Kato
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Yamada
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004379:Duodenal Neoplasms / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy / Q000401:mortality; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D000077146:Irinotecan; D007580:Jejunal Neoplasms / Q000188:drug therapy / Q000401:mortality; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin